Mao, Z. and Ong, A.C.M. (2009) Peroxisome proliferator-activated receptor gamma agonists in kidney disease - future promise, present fears. Nephron Clinical Practice, 112 (4). pp. 230-241. ISSN 1660-2110Full text not available from this repository. (Request a copy)
The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-Y isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-Y agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-Y in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-Y agonists and reflect on their potential use in 'orphan' kidney diseases.
|Keywords:||PPAR-Y agonists; Thiazolidinediones; Kidney disease; Diabetes mellitus|
|Institution:||The University of Sheffield|
|Academic Units:||The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Clinical Sciences Division North (Sheffield) > Sheffield Kidney Institute|
|Depositing User:||Miss Anthea Tucker|
|Date Deposited:||11 Aug 2009 08:58|
|Last Modified:||11 Aug 2009 09:00|